Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer

Yoshimi Noda1, Takayuki Shiroyama1,2*, Kentaro Masuhiro1, Saori Amiya1, Takatoshi Enomoto1, Yuichi Adachi1, Reina Hara1, Takayuki Niitsu1, Yujiro Naito1, Kotaro Miyake1, Shohei Koyama1, Haruhiko Hirata1, Izumi Nagatomo1, Yoshito Takeda1 & Atsushi Kumanogoh1,2,3,4

The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC) might depend on the presence of emphysema, but this association is not established. We aimed to investigate if quantitively and automatically measuring emphysema can predict the effect of ICIs. We retrospectively analyzed 56 patients with NSCLC who underwent immunotherapy at our hospital. We used the Goddard scoring system (GS) to evaluate the severity of emphysema on baseline CT scans using three-dimensional image analysis software. The emphysema group (GS ≥ 1) showed better progression-free survival (PFS) than the non-emphysema group (GS = 0) (6.5 vs. 2.3 months, respectively, p < 0.01). Multivariate analyses revealed that good performance status, GS of ≥ 1, and high expression of PD-L1 were independently associated with better PFS, while smoking status was not. In conclusion, quantitative evaluation of emphysema can be an objective parameter for predicting the therapeutic effects of ICIs in patients with NSCLC. Our findings can be used to generate hypotheses for future studies.

Immune checkpoint inhibitors have improved clinical outcomes in patients with advanced lung cancer. However, their therapeutic benefits are limited to a few patients, and the perfect predictors of these benefits remain unknown. The expression of PD-L1 and tumor mutational burden (TMB) are some tumor-related factors that might be responsible for enhancing the effects of immunotherapy, but they are imperfect. Therefore, there is a need to comprehensively evaluate multiple factors that may affect the action of ICIs in cancer patients.

Among host factors, smoking status, which increases somatic mutations and expresses neoantigens, is beneficial for ICIs in patients with advanced non-small-cell lung cancer (NSCLC)1,2. However, investigating the patients' smoking status by conducting interviews does not necessarily reflect the actual smoking exposure or its mutational effect3. A previous meta-analysis showed that emphysema detected on computed tomography (CT) was independently associated with an increased risk of lung cancer irrespective of smoking status4. The study also indicated that a shared mechanism might be involved in the pathogenesis of both emphysema and lung cancer.

However, despite this evidence, the association between treatment outcomes of ICIs and the development of emphysema has not been investigated. Therefore, we aimed to evaluate whether the quantitative evaluation of semiautomatically detected pulmonary emphysema can predict the effectiveness of ICI treatment in patients with advanced NSCLC.

1Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan. 2Department of Immunopathology, WPI, Immunology Frontier Research Center (iFReC), Osaka University, Suita, Osaka, Japan. 3Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, Japan. 4Center for Infectious Diseases for Education and Research (CiDER), Osaka University, Suita, Osaka, Japan. *email: takayuki.s12@hotmail.co.jp
**Results**

**Patient characteristics and Goddard score.** We identified 56 patients with advanced NSCLC who received monotherapy with ICIs. A total of 15 patients had a Goddard score (GS) = 0, and 41 patients had a GS ≥ 1. The median body mass index (BMI) was higher in the group of GS = 0 than in the group of GS ≥ 1 (23.2 vs 21.3 kg/m², p = 0.04). There were no significant differences in patient characteristics and laboratory findings other than BMI between the two groups (Table 1).

**Smoking history and Goddard score.** We analyzed the association between GS and smoking status (Fig. 1) and found no significant difference in the score between patients who had smoked and those who had never smoked (p = 0.35). Table 2 summarizes the immune responses to ICIs between the two groups. Although not statistically significant, the overall response rate was higher in the emphysema group than in the non-emphysema group (34.1% vs. 6.7%, p = 0.086). Figure 2 shows the Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) of both groups. The median follow-up time was 11.0 months. The emphysema group showed better PFS than the non-emphysema group (6.5 vs 2.3 months, respectively; p < 0.01) (Fig. 2A). To further clarify our findings, we divided the emphysema group into two groups—the mild emphysema group (GS 1–7) and moderate emphysema group (GS ≥ 8)—but there was no statistical difference between them (Fig. 2B).

| Age (years) | Goddard score 0 (N=15) | Goddard score ≥ 1 (N = 41) | P-value |
|-------------|------------------------|---------------------------|---------|
| Median (IQR) | 72 (64–75)             | 70 (66–74)                | >0.99   |
| Sex, n (%)   |                        |                           | 0.35    |
| Male         | 7 (46.7)               | 13 (31.7)                 |         |
| Female       | 8 (53.3)               | 28 (68.3)                 |         |
| Body mass index (kg/m²) |           |                           | 0.04    |
| Median (IQR) | 23.2 (20.9–25.0)       | 21.3 (18.9–23.2)          |         |
| ECOG PS, n (%)|                       |                           | 0.60    |
| 0            | 2 (13.3)               | 4 (9.8)                   |         |
| 1            | 9 (60.0)               | 22 (53.7)                 |         |
| 2            | 3 (20.0)               | 14 (34.1)                 |         |
| 3            | 1 (6.7)                | 1 (2.4)                   |         |
| Smoking status, n (%)|         |                           | 0.67    |
| Never        | 3 (20.0)               | 5 (12.2)                  |         |
| Current or former |          | 12 (80.0)               | 36 (87.8)|
| No. of patients evaluated by HRCT, n (%) | 14 (93.3) | 37 (90.2) | >0.99 |
| Histology, n (%)|                      |                           | 0.24    |
| Adenocarcinoma | 7 (46.7)            | 27 (65.9)                 |         |
| Squamous cell carcinoma | 4 (26.7)  | 10 (24.4)                |         |
| NOS          | 4 (26.7)               | 4 (9.8)                   |         |
| PD-L1 TPS, n (%)|                       |                           | 0.50    |
| <1%          | 2 (13.3)               | 5 (12.2)                  |         |
| 1–49%        | 2 (13.3)               | 12 (29.3)                 |         |
| ≥50%         | 9 (60.0)               | 22 (53.7)                 |         |
| Unknown      | 2 (13.3)               | 2 (4.9)                   |         |
| Treatment, n (%)|                      |                           | >0.99   |
| Nivolumab    | 4 (26.7)               | 13 (31.7)                 |         |
| Pembrolizumab| 9 (60.0)               | 23 (56.1)                 |         |
| Atezolizumab | 2 (13.3)               | 5 (12.2)                  |         |
| Treatment line, n (%)|         |                           | >0.99   |
| 1st          | 7 (46.7)               | 18 (43.9)                 |         |
| ≥2nd         | 8 (53.3)               | 23 (56.1)                 |         |
| Neutrophil-to-lymphocyte ratio |        |                           | 0.39    |
| Median (IQR) | 4.08 (3.11–5.37)       | 4.57 (2.84–6.76)          |         |
| Albumin (g/dL) |                      |                           | 0.90    |
| Median (IQR) | 3.40 (2.95–3.75)       | 3.40 (2.90–3.90)          |         |
| C-reactive protein (mg/dL) |         |                           | 0.27    |
| Median (IQR) | 1.45 (0.49–4.81)       | 0.40 (0.11–5.16)          |         |

**Table 1.** Baseline patient characteristics according to the Goddard score. *IQR* inter-quartile range, *ECOG PS* Eastern Cooperative Oncology Group performance status, *HRCT* high-resolution computed tomography, *NOS* not otherwise specified, *TPS* tumor proportion score.
Among patients with high PD-L1 expression, emphysema was associated with significantly better PFS as compared to no emphysema (21.1 vs 3.3 months, respectively, p < 0.01). On the other hand, among patients with low PD-L1 expression, there was no significant difference in PFS between patients with and without emphysema (2.7 vs 2.0 months, respectively, p = 0.31). There was a statistically significant difference in emphysema and PD-L1 status among the four groups (log-rank test for trend, p < 0.01) (Fig. 2C). The relationship between OS and emphysema showed a trend similar to that of PFS (Fig. 2D–F). The emphysema group showed better OS than the non-emphysema group (20.6 vs 10.8 months, respectively, p = 0.092) (Fig. 2D).

The outcomes of the univariate and multivariate analyses regarding PFS are shown in Table 3. In the univariate analyses, better PFS was significantly associated with high PD-L1 expression and emphysema (GS ≥ 1), while a treatment line of ≥ 2 was associated with worse outcomes. Multivariate analyses adjusted for age, Eastern Cooperative Oncology Group performance status (ECOG PS), BMI, smoking status, PD-L1 status, and GS revealed that emphysema (GS ≥ 1), good PS (PS ≤ 1), and high PD-L1 expression were independently associated with better PFS, while smoking status was not. Table 4 shows the findings of the univariate and multivariate analyses regarding OS. The univariate analysis demonstrated that high PD-L1 expression was the only factor related to better OS. However, after adjustment for age, ECOG PS, BMI, smoking status, PD-L1 status, and GS, multivariate analyses revealed that good PS (PS ≤ 1), high PD-L1 expression, and emphysema (GS ≥ 1) were independently associated with better OS, whereas smoking status was not.

Discussion
This study investigated the impact of emphysema on the efficacy of PD-1/PD-L1 inhibitor therapy in clinical practice. Our results showed that emphysema (GS ≥ 1) evaluated by semiautomatic image analysis was significantly associated with better treatment outcomes for immunotherapy, while smoking status was not. The degree of emphysema, be it mild (GS 1–7) or moderate (GS ≥ 8), did not affect the efficacy of the ICIs. While one previous study has reported a relationship between GS and the efficacy of ICIs, our study is novel because we excluded patients with oncogenic driver mutations and used semiautomatic imaging software to evaluate emphysema. Our chosen method of using image analysis software is accepted as more objective, reproducible, and technically easy.

Our study demonstrated that emphysema was correlated with better efficiency of ICIs compared to smoking status. Among the components of chronic obstructive pulmonary disease (COPD), which include emphysema and airway disease, emphysema enhances the therapeutic effect of PD-L1 blockade by exhausting the early cytotoxic CD8+ T cells. Dendritic cells exposed to an emphysema tumor microenvironment downregulate MHC class II and costimulatory molecules and upregulate PD-L1/IDO. Our results are consistent with this mechanism,
suggesting that the morphological change induced by smoking plays a more important role in improving the sensitivity of ICI than smoking itself.

Previous reports that investigated the relationship between COPD and therapeutic effects of ICI\(^7,8\) focused on airflow obstruction and not emphysema, while we focused on emphysema and did not evaluate airway components because of the lack of data on pulmonary function tests. At present, there are no data on which of these factors affect the microenvironments of lung cancer or whether both factors are related.

Figure 2. (A) Kaplan–Meier plot of the progression-free survival (PFS) in patients with or without emphysema (GS ≥ 1 vs GS = 0). (B) PFS in patients without emphysema (GS = 0), with mild emphysema (GS 1–7), or moderate emphysema (GS ≥ 8). (C) PFS in patients with or without emphysema, according to whether the PD-L1 expression is high or not. (D) Kaplan–Meier plot of the overall survival (OS) in patients with or without emphysema (GS ≥ 1 vs GS = 0). (E) OS in patients without emphysema (GS = 0), with mild emphysema (GS 1–7), or moderate emphysema (GS ≥ 8). (F) OS in patients with or without emphysema, according to whether the PD-L1 expression is high or not. GS Goddard score.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age ≥ 75 years             | 1.03 (0.49–2.17)    | 0.93                  | 1.01 (0.45–2.25)    | 0.98                  |
| Gender, Male               | 1.76 (0.90–3.47)    | 0.10                  |                        |                       |
| ECOG PS ≥ 2                | 1.75 (0.91–3.36)    | 0.096                 | 2.19 (1.09–4.42)     | 0.028                 |
| BMI ≥ 25                   | 0.77 (0.27–2.17)    | 0.62                  | 0.66 (0.22–2.01)     | 0.47                  |
| Current or former smoker   | 1.21 (0.47–3.11)    | 0.69                  | 1.23 (0.46–3.30)     | 0.68                  |
| Histologic type, Sq        | 1.68 (0.87–3.25)    | 0.12                  |                        |                       |
| PD-L1 TPS ≥ 50%            | 0.48 (0.25–0.93)    | 0.030                 | 0.45 (0.23–0.88)     | 0.020                 |
| Goddard score ≥ 1          | 0.41 (0.21–0.80)    | 0.009                 | 0.36 (0.18–0.71)     | 0.004                 |
| Treatment line ≥ 2         | 1.98 (1.03–3.82)    | 0.041                 |                        |                       |

Table 3. Univariate and multivariate analyses of risk factors related to progression-free survival. Sq squamous cell carcinoma, ECOG PS Eastern Cooperative Oncology Group performance status, BMI body mass index, TPS tumor proportion score.

suggestions that the morphological change induced by smoking plays a more important role in improving the sensitivity of ICI than smoking itself.

Previous reports that investigated the relationship between COPD and therapeutic effects of ICI\(^7,8\) focused on airflow obstruction and not emphysema, while we focused on emphysema and did not evaluate airway components because of the lack of data on pulmonary function tests. At present, there are no data on which of these factors affect the microenvironments of lung cancer or whether both factors are related.
We measured the GS using semiautomatic software and used it to predict the therapeutic effect of ICIs. Several previous studies have visually assessed the association between emphysema and lung cancer mortality. One report also demonstrated that visually assessing the presence of emphysema was suitable for predicting the risk of lung cancer. However, there is evidence of the superior efficacy of automatically evaluating emphysema, wherein a quantitative software-based method is used to detect panlobular emphysema, an important indicator of lung cancer mortality. Our results supported the efficiency of this semiautomatic method, and we believe that the method had high validity and was able to reproduce the same result and remove bias among different institutions.

Our results also indicated poor survival in patients with high PD-L1 status and without emphysema than in those with both emphysema and high PD-L1 status. Interestingly, even among patients with high PD-L1 expression, the treatment efficacy varied widely depending on the presence or absence of emphysema. Previous studies have shown that systemic inflammation, such as cachexia and sarcopenia, is associated with poor outcomes with immunotherapy, even in patients with high PD-L1 expression; however, local inflammation in the lungs may contribute to better outcomes with immunotherapy. To date, there are no data to explain these phenomena. High BMI has also been reported to be associated with ICI efficacy, but no association was found in our study. This may be partly due to the small sample size, but it was also possible that body composition may be more important to ICI efficacy than body weight; severe muscle depletion was reportedly associated with lower survival in obese patients with cancer. We believe it may be valuable to investigate the mechanisms underlying these effects and uncover the paradox of treatment failure even in patients with high PD-L1 expression or high BMI.

The present study has some limitations. First, this was a retrospective study conducted at a single center with a small sample size, precluding definite conclusions. Second, not all patients had the same imaging conditions in their CT scans, and different imaging conditions may have affected the evaluation of emphysema. Third, the follow-up time of 11.0 months in the present study may not be sufficient to evaluate overall survival. Finally, we could not assess the factor of airflow obstruction because of the lack of data on pulmonary function tests. Therefore, our findings should be regarded as hypothesis-generating for future studies.

In conclusion, we found that GS ≥ 1 evaluated by semiautomatic imaging analysis was associated with better treatment outcomes in patients who received monotherapy with ICIs. Thus, we believe that quantitative evaluation of emphysema can be used as an objective parameter to predict the therapeutic effects of ICIs in patients with advanced lung cancer. Further studies are warranted to validate our findings and resolve the method behind the underlying mechanisms of emphysema and ICIs.

### Materials and methods

#### Study design and patients

We retrospectively analyzed patients with advanced NSCLC who received mono-therapy with anti-programmed cell death-1/ligand-1 (PD-1/PD-L1) in our hospital from February 2018 to July 2019. Our exclusion criteria comprised patients who were receiving molecular targeted therapy, concurrently receiving any other anticancer therapy, or those who did not undergo chest CT within one month of starting treatment. We collected data on the patients’ backgrounds from their medical records, including age, sex, BMI, ECOG PS, smoking status, the number of patients evaluated by high-resolution computed tomography (HRCT), histology, PD-L1 tumor proportion score (TPS), clinical stage, treatment regimen and line, and baseline laboratory findings (< 2 weeks within starting treatment), which included data on C-reactive protein (CRP), serum albumin (ALB), and the neutrophil-to-lymphocyte ratio (NLR). We used BMI < ≥ 25 as the binomial cutoff for our univariate and multivariate analyses, as the previous report defined. We determined the treatment response using the Response Evaluation Criteria in Solid Tumors version 1.1. We also postulated the dates of progression, death, or the last follow-up. The cut-off date for data collection was August 30, 2020. Our study was approved by the ethics committee of Osaka University Hospital (approval no: 20445). This study was conducted in accordance with the 1964 Declaration of Helsinki and amendments. In view of the retrospective nature of the study, written informed consent from the subjects was waived by the committee.

### Table 4. Univariate and multivariate analysis of risk factors related to overall survival.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                           | HR (95% CI)         | P-value               |
|                           | HR (95% CI)         | P-value               |
| Age ≥ 75 years             | 0.69 (0.26–1.81)    | 0.45                  |
| Gender, Male               | 1.57 (0.69–3.56)    | 0.28                  |
| ECOG PS ≥ 2                | 1.78 (0.82–3.86)    | 0.15                  |
| BMI ≥ 25                   | 0.42 (0.16–1.11)    | 0.079                 |
| Current or former smoker   | 2.43 (0.57–10.26)   | 0.23                  |
| Histologic type, Sq        | 1.59 (0.72–3.51)    | 0.25                  |
| PD-L1 TPS ≥ 50%            | 0.35 (0.16–0.75)    | 0.007                 |
| Goddard score ≥ 1          | 0.52 (0.24–1.13)    | 0.099                 |
| Treatment line ≥ 2         | 1.79 (0.83–3.87)    | 0.14                  |
| Treatment line ≥ 2         | 1.79 (0.83–3.87)    | 0.14                  |
CT assessment of emphysema. To evaluate pulmonary emphysema in both lungs, we performed chest CT just before introducing ICIs. We selected CT scans with 0.5–2.0 mm slice thickness; if not available, we selected CT scans with 5 mm slice thickness.

We semiautomatically measured the GS to perform a quantitative evaluation of pulmonary emphysema on CT scans that we selected using SYNAPSE VINCENT imaging analysis software (Fujifilm Medical, Tokyo, Japan). We divided the entire field of each lung into three segments according to the horizontal lines at the top of the aortic arch, carina, and diaphragm. Using a 5-point scale for each segment, we scored the percentage of low-attenuation areas according to the corresponding Goddard classification. We considered low attenuation areas of less than –950 HU to indicate emphysema. No emphysema scored 0 points; ≤ 25% emphysema, 1 point; ≤ 50% emphysema, 2 points; ≤ 75% emphysema, 3 points; and > 75%, 4 points.

We calculated the total points from all six segments for each patient as a personal Goddard score ranging from 0 to 24. Based on these CT findings, we divided all patients into two groups: GS 0 (non-emphysema group) and GS ≥ 1 (emphysema group). The emphysema group consisted of patients with mild (GS 1–7) and moderate emphysema (GS ≥ 8). Representative CT images obtained using the Goddard score are shown in Fig. 3.

Statistical analysis. The clinical characteristics of both groups were compared using the Mann–Whitney U-test for continuous variables and Pearson's Chi-square test for categorical variables. Survival curves were analyzed using the Kaplan–Meier method and log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Differences were considered statistically significant at a p-value of < 0.05. All statistical analyses were performed using R software (version 3.3.2).

Received: 20 November 2021; Accepted: 17 May 2022
Published online: 25 May 2022

References
1. Raphael, J. et al. Predictors of survival benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis. Clin. Lung Cancer. 21, 106-113.e105 (2020).
2. El-Osta, H. & Jafri, S. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: A meta-analysis. Immunotherapy 11, 189–199 (2019).
3. Sato, K. et al. Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma. Lung Cancer 147, 12–20 (2020).
4. Smith, B. M. et al. Emphysema detected on computed tomography and risk of lung cancer: A systematic review and meta-analysis. Lung Cancer 77, 58–63 (2012).
5. Takayama, Y. et al. Coexistence of emphysema with non-small-cell lung cancer predicts the therapeutic efficacy of immune checkpoint inhibitors. In Vivo 35, 467–474 (2021).
6. Kerididani, D. et al. Cigarette smoke-induced emphysema exhausts early cytotoxic CD8+ T cell responses against nascent lung cancer cells. J. Immunol. 201, 1558–1569 (2018).
7. Mark, N. M. et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 197, 325–336 (2018).
8. Biton, J. et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am. J. Respir. Crit. Care Med. 198, 928–940 (2018).
9. Lee, H. Y., Kim, E. Y., Kim, Y. S., Ahn, H. K. & Kim, Y. K. Prognostic significance of CT-determined emphysema in patients with small cell lung cancer. J. Thorac. Dis. 10, 874–881 (2018).
10. Kim, Y. S. et al. Prognostic significance of CT-emphysema score in patients with advanced squamous cell lung cancer. *J. Thorac. Dis.* 8, 1966–1973 (2016).
11. Oelsner, E. C. et al. Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: A cohort study. *Thorax* 71, 624–632 (2016).
12. Shiroyama, T. et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. *Sci. Rep.* 9, 2447 (2019).
13. Miyawaki, T. et al. Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC. *JTO Clin. Res. Rep.* 1, 100020 (2020).
14. Cortellini, A. et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable. *J. Immunother. Cancer.* 7, 57 (2019).
15. Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. *Lancet Oncol.* 9, 629–635 (2008).
16. Panje, C. M. et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. *Radiat. Oncol.* 14, 166 (2019).
17. Goddard, P. R., Nicholson, E. M., Laszlo, G. & Watt, I. Computed tomography in pulmonary emphysema. *Clin. Radiol.* 33, 379–387 (1982).

**Acknowledgements**
This study was supported in part by the Center of Innovation program (COISTREAM) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) (to A.K.); the Japan Society for the Promotion of Science (JSPS) KAKENHI (JP18H05282 to A.K.); the Japan Agency for Medical Research and Development (AMED) (J200705023, J200705710, J200705049, JP18cm016335 and JP18cm059042 to A.K.); a grant from the Kansai Economic Federation (KANKEIREN); and Grants from Mitsubishi Zaidan1 (to A.K.). The research was designed, conducted, analysed, and interpreted by the authors entirely independently of the funding sources.

**Author contributions**
All authors meet the following ICMJE authorship criteria: all authors contributed to the intellectual content of this manuscript. Y.N. and T.S. wrote the first draft of this manuscript. Y.N. and T.S. designed this study. K.M., S.A., T.E., Y.A., R.H., T.N., Y.N., K.M., S.K., H.H., and I.N. participated in the treatment of the patient and collected the clinical data. Y.T. and A.K. made intellectual contributions and helped in patient management and writing the manuscript. All authors critically reviewed the manuscript and approved the final version.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to T.S.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022